Immutep to Collaborate with MSD to Evaluate Combo in Pivotal Phase III Trial

 

• Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)
• TACTI-004 Phase III trial will enrol approximately 750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapy
• Under the collaboration, Immutep will conduct the registrational TACTI-004 Phase III trial and MSD will supply KEYTRUDA
• Immutep retains commercial rights to efti
• Efti in combination with KEYTRUDA with or without chemotherapy has generated compelling efficacy and favourable safety in 1L NSCLC, one of the most relevant cancer indications with a high unmet medical need, across all levels of PD-L1 expression (negative, low, and high)

https://www.biospace.com/article/releases/immutep-announces-clinical-collaboration-with-msd-to-evaluate-efti-in-combination-with-keytruda-pembrolizumab-in-pivotal-phase-iii-trial/